Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
News
Job Board
CME/CE
Partners
Editorial
Subscribe
EMPOWERing the Next Generation
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
CONFERENCE REPORTER
Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.
Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.
Related Videos
Related Content
